Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
PHASE III PROGRESS
October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019...
Okay, so What’s Next for Citius Pharma (CTXR) $1.16?
Dawson James Broker/Dealer Updates. Price Target Remains at $7.00.
"OK, So what’s Next? Topline data from the superior efficacy...
VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).
Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop...
Stand Down V: MAGA. Each Crossing $1 Trillion, Microsoft, Amazon, Google, and AAPL.
Is this today's version of the Nifty 50?
Microsoft $1.3...
Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...
Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially...
CoronaVirus Watch List Stocks in the News (Bloomberg, Benzinga).
INITIAL WATCHLIST: CoronaVirus Watch List | Superbug Stock Review
Aethlon Medical, Inc. (NASDAQ: AEMD) $2.40 Alpha Pro Tech, Ltd. (NYSE: APT)...
Biotech 5 Pack. 5 Biotech Stocks We Expect to Double in 2020.
Our First Newsletter of 2020, We Come out Swinging!
Yes, you read it right. Five of our favorite...
New Report: Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.
Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the...
Citius Pharma (CTXR) Corporate Presentation (Jan 2020).
In the above graphic, the catheter can get infected by bacteria and most typically see evidence of the infection (see gross graphic...
Oramed (ORMP) $5.24, Focused on Pill Form Insulin. Is China First?
New technology could revolutionize market of 500 million diabetes patients (i24 News).